Skip to main content

Table 3 Percent completing M6 and probability of retention at M3 and M6 by baseline medical cannabis use in 1011 participants

From: The impact of non-medical cannabis legalization and other exposures on retention in longitudinal cannabis research: a survival analysis of a prospective study of Canadian medical cannabis patients

Baseline cannabis use Completed M6 (%) Kaplan–Meier estimator
Probability of remaining in study
M3 M6 P
Cannabis use per week (g)     0.567
  < 5 211/495 (42.6) 0.74 0.43  
  ≥ 5 208/505 (41.2) 0.72 0.41  
Frequency of cannabis use per week     0.587
  < 14 186/428 (43.5) 0.72 0.43  
  ≥ 14 233/571 (40.8) 0.73 0.41  
Currently using Tilray extract products     0.751
  No 165/381 (43.3) 0.71 0.43  
  Yes 254/619 (41.0) 0.74 0.41  
Preferred type of cannabis     0.044
  THC 105/239 (43.9) 0.72 0.44  
  High CBD 174/461 (37.7) 0.73 0.38  
  No preference 139/286 (48.6) 0.74 0.49  
Primary method of use      < 0.001
  Vaporizer—cannabis flower 99/167 (59.3) 0.80 0.59  
  Vaporizer/nail—cannabis extracts 2/10 (20.0) 0.50 0.20  
  Joint 73/194 (37.6) 0.71 0.38  
  Oral 209/546 (38.3) 0.72 0.38  
  Pipe 11/33 (33.3) 0.58 0.33  
  Waterpipe/bong 18/35 (51.4) 0.80 0.51  
  Topical 5/11 (45.5) 0.82 0.45  
Primary method of use     0.027
  Inhaled 203/439 (46.2) 0.74 0.46  
  Orally ingested 209/546 (38.3) 0.72 0.38  
  1. M3 = month 3 timepoint, M6 = month 6 timepoint